Article – Enteromix, Russian cancer vaccine achieves 100% efficacy in clinical trials

Jai Siya Ram

100% efficacy reported in preclinical and early clinical trials
Enteromix, an mRNA-based personalized cancer vaccine, has shown 100% effectiveness and safety in early-stage testing, according to reports. The announcement came from official sources during the Eastern Economic Forum.
Target cancer types and observed outcomes
The vaccine’s primary application appears to be against colorectal cancer, with trials noting significant tumor shrinkage (60–80%) and improved survival rates. Research on vaccines tailored for glioblastoma (an aggressive brain cancer) and various forms of melanoma, including ocular melanoma, is underway.

mRNA technology meets oncolytic viruses
Enteromix employs mRNA vaccine technology—similar to COVID-19 vaccines—but is personalized to match each patient’s tumor RNA profile. It reportedly uses a combination of four non-pathogenic viruses engineered both to destroy cancerous cells and activate the patient’s anti-tumor immunity.
Collaborating institutions
Developed by the Federal Medical and Biological Agency (FMBA) in collaboration with Russia’s National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology (EIMB), the vaccine leverages expertise across virology and oncology research.
Clinical Trial Status
Phase I human trials underway
Russia initiated an open-label, single-center Phase I clinical trial involving approximately 48 volunteers in June 2025. The trials are reported to show very low toxicity, with participants tolerating the vaccine well and displaying complete or significant tumor regression.
Safety and preliminary outcomes
Early human trials revealed no serious side effects, robust safety even with repeated doses, and elimination or dramatic reduction of tumors in several patients.

Awaiting regulatory approval
With promising preclinical and Phase I results, Enteromix now awaits authorization from Russia’s Ministry of Health before wider clinical rollout.
Global significance
If validated through larger Phase II/III trials, Enteromix could herald a new era of personalized cancer immunotherapy, potentially offering safer and more effective treatment than traditional options like chemotherapy or radiation.